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Abstract
This paper evaluates the suitability of various compressors available in Europe to generate and deliver tobramycin nebulizer
solution to cystic fibrosis patients from the PARI LC PLUS jet nebulizer. This evaluation has been undertaken (i) by establishing
an in vitro equivalence to the DeVilbiss PulmoAide compressor (operating at 4.6 lymin) proven effective in US clinical trials,
and (ii) by determining equivalent in vitro performance of the LC PLUS nebulizer driven by alternative airflows. Equivalent
performance is judged as having both an aerosol output and aerosol size within "10% of that obtained with the LC PLUSy
PulmoAide combination. The two different in vitro methodologies applied to this investigation were based on the British Standard
and a European Standard to assess nebulizer output. The results demonstrate that a wide range of compressed airflow rates
generate aerosol output from the PARI LC PLUS equivalent to that obtained from the PulmoAide compressor. This range of
airflows encompasses many compressors commonly available in Europe.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The PARI LC PLUS jet nebulizer powered by the US
DeVilbiss PulmoAide compressor was chosen for deliv-
ery of tobramycin nebuliser solution (TNS) to cystic
fibrosis (CF) patients and was used in US clinical trials
(which subsequently demonstrated the safety and effi-
cacy of TNS) w1x. The reasons for this choice were that
both the LC PLUS nebulizer and PulmoAide compressor
were (and are) widely available in North America.
Further, the rate of aerosol output and total overall
output were considered ideal for this drug formulation
and patient group. The particle size distribution was
heterodisperse and was thought to contain a high pro-
portion of particles in a size range (2–5 mm) thought
ideal for targeting aerosol in the central airways w2x,
where TNS is thought to be most effective in the CF
respiratory tract.
The LC PLUS nebulizer has a design commonly
referred to as ‘breath enhanced’, meaning that, although
it continuously produces aerosol (even during patient
exhalation), the aerosol emitted during the inhalation
phase is greater than aerosol output during exhalation.
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During inhalation, make-up air generated by patient
inhalation is entrained through the nebulizer. The nebu-
lizer is designed to allow this entrained air to ‘pick up’
additional aerosol, thus enhancing the rate of aerosol
output. This design has theoretical and practical advan-
tages over ‘constant output’ nebulizer designs w3,4x as
it results in less waste, greater aerosol output rates, and
therefore faster delivery times than conventional ‘con-
stant output’ nebulizer designs.
There is a further little recognized, but critically
important, advantage of breath enhanced nebulizer
design over constant output nebulizer design—the sta-
bility of aerosol size w5x. Nebulized aerosol is made up
of small water droplets, when they are released from the
nebulizer, containing a drug in solution (as with TNS)
or suspension. The size of these droplets, when they are
released from the nebulizer, is only stable as long as
they are enshrouded in air with 100% relative humidity.
Complete humidification of released air is normally the
case within the aerosol emitted from most nebulizers.
However, with conventional nebulizer designs, the ambi-
ent air entrained during patient inhalation mixes with
the released nebulized aerosol in varying proportions
depending on the inhalation flow rate and the rate of
output from the nebulizer. The nebulized aerosol is
mixed into ambient air and evaporates virtually instan-
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Fig. 1. Schematic of a traditional ‘constant output’ nebulizer illus-
trating the evaporative effect of particle size after mixing with ambient
(low relative humidity) entrained air in the nebulizer T-piece (from
Nerbrink et al. w5x).
Fig. 2. Schematic of a ‘breath-enhanced’ nebulizer illustrating the sta-
bility of aerosol size in the ;99.5% relative humidity environment
of ambient air entrained and humidified by passing through the neb-
ulizer interior (from Nerbrink et al. w5x).
taneously w6x until the surrounding air is fully humidi-
fied, whatever the ratio of entrained, partly humidified
air to fully humidified ‘nebulized air’. This evaporative
effect cannot be avoided and can significantly reduce
the size of inhaled aerosol obtained from constant output
nebulizer designs. A schematic illustrating this evapo-
rative process is shown in Fig. 1.
The extent of the evaporation and consequent reduc-
tion of nebulized aerosol size depends on the capacity
of entrained air to absorb water, which is dependent on
total entrained flow, ambient temperature and ambient
humidity. Thus, the size of nebulized droplets inhaled
from constant output nebulizer designs is inherently
unstable. In contrast, breath-enhanced nebulizer designs
such as the PARI LC PLUS entrain ambient air through
rather than over the nebulizer. All evaporative gains are
made from the large reservoir solution, which exhibits
a slight increase in solute concentration; however, this
has little—if any—significant effect. Thus there is no
post-production effect of evaporation from breath-
enhanced nebulizers (Fig. 2).
Besides the theoretical advantages of the PARI LC
PLUS over many other designs, clinical trials in the
USA have shown the nebulizer to be safe and efficacious
in delivery of TNS. However, the nebulizer system used
for delivery included the LC PLUS nebulizer operated
by a specific compressor, the DeVilbiss PulmoAide.
While the PARI LC PLUS jet nebulizer is widely
available in Europe, power supply differences between
the continents mean that the DeVilbiss PulmoAide
compressor is not available in Europe in the US power
supply configuration.
It is the intention of this paper to evaluate the
technical suitability of various compressors available in
Europe to generate and deliver TNS effectively to CF
patients from the PARI LC PLUS jet nebulizer, firstly
by establishing an in vitro equivalence to the US
DeVilbiss PulmoAide compressor. Two studies are
described which were undertaken to evaluate the in vitro
aerosol output from the TNS delivery system licensed
in the US trials (LC PLUS nebulizer and US PulmoAide
compressor), and then to investigate what range of
compressed airflow rates driven through the PARI LC
PLUS nebulizer would result in an aerosol output and
aerosol size equivalent to that from the PulmoAide
compressor. From the outset of this study design, ‘equiv-
alent’ aerosol output rates and aerosol size were consid-
ered to be those within "10% of those from the LC
PLUSyPulmoAide nebulizer system. Finally, the ‘win-
dow’ of aerosol output and size considered equivalent
to the PulmoAide compressor would be compared to
airflows driven through the PARI LC PLUS nebulizer
by a sample of compressors commonly available in
Europe.
2. Methods
Two in vitro methods were chosen to evaluate aerosol
output and size from the LC PLUS over a range of
compressed airflows. One method is contained in a
British Standard w7x, and another from a new European
Standard method only recently published w8x. The basic
principles of these methods are described elsewhere w9x
and are summarized in Table 1.
These two methods are fundamentally different in
methodology. Of the two, the draft European Standard
should be considered more clinically representative
because it measures solute size distribution (obtained
by low flow cascade impaction and analysis of solute
residue) rather than volume size distribution (obtained
from laser diffraction) used in the now dated British
Standard. Furthermore, the draft European Standard
takes into account patient breathing patterns.
Both methods were used to evaluate aerosol output
from the LC PLUS nebulizer at y40, y20, q20 and
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Table 1
Summary of differences in in vitro assessment methods to assess nebulizer performance embodied in British Standard BS7711 part 3 and the
European nebulizer standard
British Standard European Standard
Aerosol output Simulates constant inhalation of 20 lymin to determine Simulates a breathing pattern with a
aerosol output in 1 min and then to measure all aerosol released sinus flow of 500 ml=15 rpm
Aerosol size Laser diffraction of ‘standing cloud’ Low flow cascade (2 lymin) from a
simulated inhalation of 15 lymin
Table 2
Results of assessment of aerosol output and aerosol size from the PARI LC PLUS nebulizer using British Standard in vitro methods
Compressor flow rate (lymin) 2.6 3.6 4.6 5.4 6.5
Compressor pressure (psi) 7.1 13.9 20.2 26.2 35.3
Aerosol size
MMD (mm) 7.20 5.25 4.83 4.75 3.98
-2 mm (%) 7.1 13.4 16.7 17.6 22.6
-5 mm (%) 31.0 49.2 53.7 54.5 64.0
Aerosol between 2 and 5 mm (%) 23.9 35.8 37.0 36.9 41.2
Aerosol output after 1 min (ml) 111 223 288 403 496
Aerosol output after 15 min (ml) 1430 3132 3178 3275 3050
Total aerosol output (ml) 2341 3392 3178 3275 3050
Time to nebulization (min, s) 289200 169200 119380 89190 69280
Mean aerosol output, aerosol size vs. nebulizer flow and pressure. In all experiments, ns6.
q40% of the flow achieved with the PulmoAide com-
pressor used in the US clinical trials. The US PulmoAide
compressor was operated using an Omron mains power
converter to convert UK power (240 V at 50 Hz) to US
power equivalent (115 V at 60 Hz). The flow rate
through the LC PLUS from the US PulmoAide was
measured using a bubble flow meter and was found to
be approximately 4.6 lymin. TNS supplied in 5-ml
ampoules (PathoGenesis Corp.) were used as the test
solution in all cases. At each flow rate, mean aerosol
outputs and mean aerosol sizes were calculated from six
samples (three nebulizers, each sampled in duplicate).
Having investigated and proven a consistent and stable
ratio between tobramycin drug and salt solute concen-
tration within all samples of nebulized aerosol, chloride
analysed electrochemically was used as a solute marker
rather than assaying tobramycin antibiotic by HPLC in
every case. Results of aerosol output are expressed in
ml volumes or initial drug solution volume fill.
To evaluate the suitability of alternative air compres-
sors, a range of electrically operated compressors were
in turn connected to a PARI LC PLUS nebulizer, and
back pressure and resulting airflow were measured
during operation of a dry nebulizer. Back pressure was
measured using a Budenburg pressure gauge connected
just behind the nebulizer using a T-piece, which allowed
pressure to be read to the nearest 0.1 psi. Airflow
generated through the nebulizer was measured for each
compressor by connecting the air jet by a short length
of tubing to a bubble flow meter, and it was calculated
by timing the displacement of a bubble film over a
known air volume.
3. Results
Results from the in vitro assessment using British
Standard methodology are shown in Table 2, and Figs.
3 and 4. Results obtained using methodology described
in the European Standard are shown in Table 3, and
Figs. 5 and 6. All data are presented as the mean of six
measurements.
Results of the measurement of airflow and back
pressure over a representative sample of air compressors
commonly available in Europe are presented in Table 4.
4. Discussion
Despite differences in absolute estimates of both
aerosol output and aerosol size between the two meth-
ods, both methods generally show a similar trend (Figs.
3–6). Regardless of which test method results are
considered, both demonstrate equivalence in aerosol
output and aerosol size across most of the range of
compressed airflows tested, with the exception of aerosol
output obtained at the lowest airflow (2.6 lymin). The
main variable in aerosol output at airflows between 3.5
and 6.5 lymin was the time required for complete
nebulization.
In general, a shorter nebulization time is more desir-
able than a longer nebulization time. Thus, when it
comes to delivering TNS from the PARI LC PLUS, the
best compressor(s) are the most powerful ones. How-
ever, other compressors might be more easily available
in different areas across Europe, and these may be
favoured because of cost and availability. In any case,
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Fig. 3. Total aerosol output (m) and aerosol size (d) as MMD vs. nebulizer flow rate using British Standard in vitro assessment methods (data
taken from Table 2). Aerosol size summarized as the mass median diameter (MMD).
Fig. 4. Total aerosol output and aerosol size vs. nebulizer flow rate using British Standard in vitro assessment methods (data taken from Table
2). Aerosol size shown as a histogram depicting three ranges of aerosol size (-2 mm (j), 2–5 mm (Y), and )5 mm (Z)).
Table 3
Results of assessment of aerosol output and aerosol size from the PARI LC PLUS nebulizer using European Standard in vitro methods
Compressor flow rate (lymin) 2.6 3.7 4.6 5.4 6.5
Compressor pressure (psi) 7.1 14.3 20.1 25.7 34.6
Aerosol size
MMAD (mm) 6.1 5.2 5.5 5.3 4.9
-2 mm (%) 17 17 17 19 23
-5 mm (%) 42 48 46 48 51
Aerosol between 2 and 5 mm (%) 24 30 28 28 27
Aerosol output 1 min (ml) 86 158 167 195 204
Aerosol output 1–15 min (ml) 800 1790 1714 1621 1521
Aerosol output 0–15 min (ml) 886 1948 1881 1816 1725
Aerosol output )15 min (ml) 667 150 – – –
Total aerosol output (ml) 1553 2098 1881 1816 1725
Time to complete nebulization (min, s) 309290 169160 119250 99040 79550
Mean aerosol output, aerosol size vs. nebulizer flow and pressure. In all experiments, ns6.
nebulization times longer than 10 min challenge patient
compliance and acceptability. Compressors with delivery
times beyond 15 min should not be recommended for
the delivery of TNS, as )15 min is considered unac-
ceptably long and unnecessary when so many compres-
sors are available to deliver the same drug aerosol dose
more rapidly. The sample of compressors selected for
test is by no means comprehensive. Additional com-
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Fig. 5. Total aerosol output (m) and aerosol size (d) as mass median aerodynamic diameter (MMAD) vs. nebulizer flow rate using European
Standard in vitro assessment methods (data taken from Table 3). Aerosol size summarized as MMAD.
Fig. 6. Total aerosol output and aerosol size vs. nebulizer flow rate using European Standard in vitro assessment methods (data taken from Table
3). Aerosol size shown as a histogram depicting three ranges of aerosol size (-2 mm (j), 2–5 mm (Y), and )5 mm (Z)).
Table 4
Air flow rate and operating back pressure from a range of portable air compressors commonly available in Europe, and a judgement on whether
they are acceptable for the delivery of TNS
Flow (lymin) Back pressure (psi) Acceptable for delivery of TNS
Aiolos Hercules 7.99 43.5 Above range tested
Aiolos Albatross 6.83 36.0 Above range tested
Medix ECONO-neb 6.24 31.9 Yes
AFP-Tourer 5.84 29.2 Yes
DeVilbiss Pulmo-Aide Traveler 5.23 24.2 Yes
PARI Master 5.01 23.5 Yes
Mefar MPV 3u Tiefeninhalator 5.01 23.1 Yes
DeVilbiss SunMist 4.86 21.8 Yes
US DeVilbiss PulmoAide 4.65 20.2 Yes
UK DeVilbiss PulmoAide 4.46 18.8 Yes
Medic-Aid Porta-neb 4.44 18.8 Yes
PARI boy 4.12 16.8 Yes
PARI Walkboy 2.77 8.1 No
Note: this list is not intended to be exhaustive or exclusive.
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pressors can be readily assessed for suitability for
delivery of TNS by measuring either the back pressure
or airflow—of the two, back pressure is perhaps the
simpler, though care should be taken to ensure the
pressure gauge is calibrated and situated close to the
nebulizer, and pressure measurements should be made
during operation of the nebulizer.
5. Summary
The PARI LC PLUS nebulizer is a good design for
the delivery of TNS on theoretical grounds. The PARI
LC PLUS nebulizer generates relatively high rates of
aerosol output with relatively low residual volumes
compared with many other jet nebulizers. The aerosol
size from the PARI LC PLUS nebulizer is heterodis-
perse, and a large proportion is contained in a size range
thought ideal for deposition in the central airways (2–5
mm). Furthermore, the aerosol released and inspired by
the patient during treatment is stable because of the
breath-enhanced PARI LC PLUS design—this is not
true of aerosol released from constant output nebulizer
designs.
Delivery of TNS through the PARI LC PLUS nebu-
lizer driven by the US PulmoAide compressor has
proven to be safe and efficacious in clinical trials.
In vitro assessment of aerosol output and size has
been determined from the LC PLUSyPulmoAide nebu-
lizer system, as has aerosol output and aerosol size from
a range of pressureyflows above and below that found
for the PulmoAide compressor. Two approaches to in
vitro assessment of nebulizer performance were used in
this study. Although the absolute measurements from
the two methods are different, trends in the results are
similar.
Aerosol output equivalent to the PARI LC PLUSy
PulmoAide nebulizer system, in terms of delivered dose
and particle size (within "10%), can be obtained
through a wide range of compressed airflows ranging
from 3.6 to 6.5 lymin. The main difference is that larger
airflows resulted in a shorter time needed to deliver
aerosol output equivalent to the PARI LC PLUS nebu-
lizer driven by the PulmoAide compressor.
Most European compressors fall within the acceptable
range of equivalent airflow (Table 4).
6. Conclusion
Clinical trials have shown that safe and efficacious
TNS nebulized aerosol delivery can be obtained using
the PARI LC PLUS nebulizer driven by the PulmoAide
compressor. In vitro results presented above demonstrate
that an equivalent dose is readily achieved from the
PARI LC PLUS nebulizer using a wide range of alter-
native compressors commercially available throughout
Europe.
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